CM Life Sciences II , a SPAC backed by Keith Meister’s Corvex Management LP and life-sciences investor Casdin Capital, could finalize a merger with SomaLogic that values the company at around $1.25 billion as soon as today, The Wall Street Journal reports.
The deal has the additional backing of investors including SoftBank Group subsidiary SB Management, Cathie Wood’s ARK Investment Management and gene-sequencing company Illumina, who will supply SomaLogic with a $375 million PIPE. Read more.
